SML0330
S3I-201
≥97% (HPLC)
Synonym(s):
2-Hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid, NSC 74859
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C16H15NO7S
CAS Number:
Molecular Weight:
365.36
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: >10 mg/mL
storage temp.
−20°C
SMILES string
Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc2ccc(C(O)=O)c(O)c2
InChI
1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)
InChI key
HWNUSGNZBAISFM-UHFFFAOYSA-N
Application
S3I-201 has been used as a signal transducer and activator of transcription 3 (STAT3) inhibitor:
- to confirm the role of STAT3 phosphorylation in interleukin (IL)-33 production in lung epithelial cells and IL-22 mRNA expression in sorted group 3 innate lymphoid cells (ILC3s)
- to study the cellular response of STAT3 triggered by β-hexaclorocyclohexane (β-HCH) in various cell lines
- to examine the influence of STAT3 in response to angiotensin II (ang II) on induction of fibrotic proteins in kidney epithelial cells
Biochem/physiol Actions
Inhibition of signal transducer and activator of transcription 3 (STAT3) activity by S3I-201 may be a potential therapeutic strategy for hypertensive kidney disease.
S3I-201 is a cell-permeable Stat3 inhibitor that binds to the Stat3-SH2 domain, prevents Stat3 phosphorylation/activation, dimerization, and DNA-binding.
S3I-201 is a cell-permeable Stat3 inhibitor.
Still not finding the right product?
Explore all of our products under S3I-201
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Gaurav Kumar et al.
Radiology, 286(2), 524-536 (2017-09-08)
Purpose To (a) identify key expressed genes in the periablational rim after radiofrequency ablation (RFA) and their role in driving the stimulation of distant tumor growth and (b) use adjuvant drug therapies to block key identified mediator(s) to suppress off-target
Hui Fang et al.
The Journal of pathology, 245(1), 114-125 (2018-02-23)
Bullous pemphigoid is an autoimmune inflammatory disorder characterized by the presence of autoantibodies against bullous pemphigoid autoantigens, leading to dermal-epidermal separation with consequent blister formation. However, whether and how the components of blister fluid exacerbate the progression of bullous pemphigoid
Safiye E Sarper et al.
Scientific reports, 8(1), 11208-11208 (2018-07-27)
Runx1 deficiency results in an anteriorly specific cleft palate at the boundary between the primary and secondary palates and in the first rugae area of the secondary palate in mice. However, the cellular and molecular pathogenesis underlying such regional specificity
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML0330-25MG | 04061832633367 |
| SML0330-5MG | 04061832633374 |